Alkermes stock fell 5.2% in pre-open trading to $50.00 after the company published its Q2 2026 financial results ahead of the market open. The quarter delivered a headline earnings beat but was undercut by a full-year revenue guidance midpoint that fell short of Street expectations.
Earnings snapshot
Adjusted earnings per share were reported at $0.00, beating the consensus estimate of -$0.02. Revenue totaled $496 million, ahead of the $459 million forecast and representing 27% year-over-year growth. Despite those positive metrics, the company reaffirmed a full-year 2026 revenue guidance midpoint of $1.785 billion, below the analyst consensus of $1.81 billion. That guidance gap was a principal factor cited by market participants as the reason for the early decline in the stock.
Market reaction and positioning
The pre-market sell-off came against a backdrop of elevated investor positioning. Shares of Alkermes had risen about 88% year-to-date leading into the report. Short interest stood at roughly 10.7% of the float, creating conditions in which a guidance shortfall and a crowded long trade could fuel profit-taking. That combination appears to have amplified the move lower following the guidance announcement.
Broader indices offered limited support for the name. The Nasdaq composite showed mild weakness, while the S&P 500 and Dow Jones Industrial Average were marginally positive, suggesting the pressure on Alkermes was driven largely by company-specific developments rather than a generalized market decline.
Drivers of the quarter
The LUMRYZ franchise, focused on narcolepsy and added through Alkermes' earlier acquisition of Avadel Pharmaceuticals for $2.4 billion, contributed meaningfully to the revenue outperformance. At the same time, integration costs associated with that acquisition and the tempered revenue outlook appear to have weighed on investor sentiment.
Analyst response
Piper Sandler reacted positively to the results, raising its price target on the stock to $65 from $43 and maintaining an Overweight rating. The firm argued the company remains undervalued at its current enterprise value. Nevertheless, that analyst optimism did not stop the pre-market decline.
Near-term outlook
Taken together, the early trading pullback reflects a market that had priced in a strong quarter and was surprised by the guidance midpoint coming in below consensus. What would otherwise have been characterized as a positive quarterly report turned into a short-term headwind for a stock trading near its 52-week high of $55.67.
Note: This article presents the company-reported figures and market responses related to Alkermes' Q2 2026 results and does not add any additional numeric or historical detail beyond those provided.